Allogene Therapeutics
Anton Nguyen is a highly experienced Principal Scientist currently contributing to ArsenalBio and Allogene Therapeutics, where significant leadership in flow cytometry and assay development is demonstrated. With a background at Pfizer as a FACS Core Scientist and previous roles at Nodality Inc., Zyngenia, Inc., diaDexus, Inc., and Chiron Corporation, Anton has extensive expertise in protein sciences, assay standardization, and laboratory management. Educational credentials include a Master’s degree in Cellular & Molecular Biology from San Francisco State University and a Bachelor’s degree in Biochemistry from the University of California, Davis.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.